Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease
Küçük Resim Yok
Tarih
2007
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Biomed Central Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
To evaluate the predictability of urine calcium (Ca2+) and deoxypyridinoline (DPD) in the assessment of response to palliative radiation therapy (RT) for metastatic bone disease. Forty-two patients with osteolytic bone metastases from breast or lung primaries were enrolled in this study. Serial urine Ca2+ and DPD measurements were performed before RT, six weeks, and twelve weeks afterwards. All eligible patients received a total of 30 Gy RT in 3 Gy daily fractions. Pre-irradiation mean urine Ca+2 and DPD levels were 16 +/- 3.7 g/mu mol/dL, and 89.2 +/- 61 pmol/mu mol crea. Both were significantly higher than normal range. A significant correlation between pre-irradiation Ca+2 (r=0.6, p<0.001), DPD (r=0.8, p<0.001) levels and the extent of bone metastases were detected. Thirty-six patients (Group I) were alive without disease progression outside the radiation portal. Urine Ca2+ and DPD levels demonstrated a significant and progressive decrease following RT in Group I patients (p<0.001). Clinical and radiological evaluation revealed occurrence of new bone metastases in six patients (Group II), with concurrent significant increase in concentrations of urine DPD and Ca+2 (p=0.006 for Ca+2 and p=0.009 for DPD, respectively). Urine Ca+2 and DPD levels can be used for assessment of response of bone to local irradiation, and are able to predict further progression of bone metastases in cancer patients.
Açıklama
Anahtar Kelimeler
urine calcium, deoxypyridinoline, palliative radiotherapy
Kaynak
Journal of Experimental & Clinical Cancer Research
WoS Q Değeri
Q4
Scopus Q Değeri
N/A
Cilt
26
Sayı
4
